3-methyl-1',2',3',6'-tetrahydro-2,4'-bipyridine | 630118-73-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-methyl-1',2',3',6'-tetrahydro-2,4'-bipyridine
• 英文别名: 3-Methyl-2-(1,2,3,6-tetrahydropyridin-4-yl)pyridine
• CAS: 630118-73-9
• 化学式: C₁₁H₁₄N₂
• mdl: MFCD09029903
• 分子量: 174.246
• InChiKey: KZGNFYYDTXHWCN-UHFFFAOYSA-N

物化性质

• 沸点：
  314.1±42.0 °C(Predicted)
• 密度：
  1.040±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methyl-1',2',3',6'-tetrahydro-2,4'-bipyridine 以11 mg (31%)的产率得到2-(3-cyano-3',6'-dihydro-2,4'-bipyridin-1'(2'H)-yl)-N-(4-fluorophenyl)acetamide
  参考文献：
  名称：

  Acetamides and benzamides that are useful in treating sexual dysfunction

  摘要：

  本发明涉及使用式(I)的化合物治疗性功能障碍，以及含有式(I)化合物的组合物用于治疗性功能障碍。

  公开号：

  US20040029887A1
• 作为产物：
  描述：

  TERT-BUTYL 4-(3-METHYL-2-PYRIDYL)-1,2,3,6-TETRAHYDRO-1-PYRIDINE-CARBOXYLATE 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 0.25h， 生成 3-methyl-1',2',3',6'-tetrahydro-2,4'-bipyridine
  参考文献：
  名称：

  Oximes and hydrazones that are useful in treating sexual dysfunction

  摘要：

  本发明涉及用于治疗性功能障碍的肟和腙的公式（I）化合物，以及含有用于治疗性功能障碍的公式（I）化合物的组合物。

  公开号：

  US20050176727A1

文献信息

• DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF
  申请人：Synaptic Pharmaceutical Corporation

  公开号：EP1246847A2

  公开（公告）日：2002-10-09
• ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION
  申请人：Abbott Laboratories

  公开号：EP1509213A2

  公开（公告）日：2005-03-02
• HETEROCYCLIC COMPOUNDS
  申请人：Shionogi & Co., Ltd.

  公开号：EP2709609B1

  公开（公告）日：2017-10-04
• US7528134B2
  申请人：——

  公开号：US7528134B2

  公开（公告）日：2009-05-05
• [EN] DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF<br/>[FR] ADN CODANT POUR UN RECEPTEUR HUMAIN DE L'HORMONE DE CONCENTRATION DE LA MELANINE (MCH1) ET SES APPLICATIONS
  申请人：SYNAPTIC PHARMA CORP

  公开号：WO2002002744A2

  公开（公告）日：2002-01-10

  This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequence of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention provides a method of modifying the feeding behavior of a subject which comprises administering to the subject an amount of an MCH1 antagonist effective to decrease the body mass of the subject and/or decrease the consumption of food by the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's depression and/or anxiety.